HealthProves
Accueil/Fabricants/Bryant Ranch Prepack
Profil du fabricant

Bryant Ranch Prepack

Société pharmaceutique88 produits suivis
88
produits suivis
4 705 846
total des notifications
788
rappels enregistrés
68,5%
graves au total
Produits
affichage de 88 sur 88
ProduitApprouvéNotifications ↓Signal principalRappels
1983393 086Insuffisance cardiaque congestive14
1953374 035Sinusite2
2000359 779Médicament inefficace pour une indication non approuvée25
2004267 198Syndrome de sevrage10
1996243 012Diabète de type 265
—195 098Maladie rénale chronique17
1997188 609Diabète de type 212
2007181 371Brûlure chimique de la peau4
1984153 758Goutte7
1981133 343Bradycardie5
1995131 745rejet de greffe9
2002129 920syndrome sérotoninergique11
1993129 795syndrome sérotoninergique0
2002124 895syndrome sérotoninergique1
1982112 882Myélome à plasmocytes19
—99 522Asthme1
198395 444Trouble de l'apprentissage22
199283 951Fibrillation auriculaire27
195470 807Problème économique7
199661 926Poussée de sclérose en plaques4
199660 482Poussée de sclérose en plaques4
199460 122Diminution du glucose sanguin14
—60 053Fibrillation auriculaire0
—55 871Trouble de l'apprentissage14
198149 201Suicide accompli24
195547 736Condition préexistante améliorée47
201146 910Mutation virale identifiée5
200144 739Condition préexistante améliorée46
201237 628incontinence urinaire0
198137 190Suicide accompli0
197237 185Maladie rénale chronique44
—34 483Condition préexistante améliorée12
198234 050Fibrillation auriculaire15
197233 218Maladie rénale chronique11
200733 035Bradycardie7
199425 624Rétention hydrique6
198424 178Hypoglycémie4
197422 513Trouble de la régulation de la température100
199921 059cancer du sein métastatique2
199920 653Glioblastome0
198919 859Lipodystrophie acquise0
199119 328Douleur oculaire17
196718 910Hypersensibilité médicamenteuse14
199718 237Syndrome des jambes sans repos13
199216 314Intoxication accidentelle0
195215 902réaction médicamenteuse paradoxale3
200415 305Triglycérides sanguins augmentés3
—13 982Migraine0
200313 824Démence7
—13 716Allergie alimentaire0
196413 177Maladie rénale chronique0
198412 988bébé de faible poids à la naissance20
197312 193Rougeur17
199111 134Vascularite4
197311 040Insuffisance rénale terminale0
—10 538Migraine0
199410 007Fissures cutanées23
—8 434augmentation de la pression intraoculaire0
19957 843Complication neurologique de l'anesthésie3
—7 700Mort-né1
19937 469Amaurose fugace4
19977 285coma hypoglycémique2
20057 280Insomnie initiale0
—7 035Maladie rénale chronique0
19936 619Psoriasis6
19916 351Maladie rénale chronique3
19926 276Perforation d'ulcère duodénal2
—6 066Œdème périphérique0
19855 377résidu de produit présent2
—5 103Allongement du complexe QRS à l'électrocardiogramme2
19964 791perte de sensibilité0
19844 229Amaurose fugace0
20014 152tic0
—4 056Diabète de type 20
19413 863Vascularite pulmonaire2
19953 794coma hypoglycémique4
19593 533Arrêt respiratoire4
—3 478Lésion musculaire6
19973 404Numération formule sanguine anormale1
19843 286Corps flottants du vitré5
20013 156Complication de sédation2
—2 853Constipation0
19732 245Ulcère cutané1
—2 169vertige0
20011 632Complication de sédation0
19581 575Anémie néphrogénique0
19791 448Pharyngite0
—784Stomatite0
Historique des rappels · 50 enregistrés
DateClasseMotifFabricant
2 juin 2026IIIPresence of foreign substanceANI Pharmaceuticals, Inc.
29 mai 2026IIFailed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hour timepoint.Golden State Medical Supply Inc.
27 mai 2026IIFailed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.Lannett Company Inc.
29 avr. 2026IICGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limitZydus Pharmaceuticals (USA) Inc
29 avr. 2026IICGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limitZydus Pharmaceuticals (USA) Inc
9 avr. 2026IIFailed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.The Harvard Drug Group LLC
20 mars 2026IICGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.Leading Pharma, LLC
10 janv. 2026IIPresence of Foreign SubstanceGraviti Pharmaceuticals Private Limited
26 nov. 2025IIIFailed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.SUN PHARMACEUTICAL INDUSTRIES INC
18 nov. 2025IIICross Contamination with Other ProductsGlenmark Pharmaceuticals Inc., USA
20 oct. 2025IIFailed Dissolution SpecificationsGolden State Medical Supply Inc.
10 oct. 2025IIFailed Dissolution SpecificationsLannett Company Inc.
10 oct. 2025IIFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC
10 oct. 2025IIFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC
19 sept. 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sept. 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sept. 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sept. 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
3 sept. 2025IIFailed Impurities/Degradation SpecificationsGlenmark Pharmaceuticals Inc., USA
19 juin 2025IIDefective container; blister packaging inadequately sealed.The Harvard Drug Group LLC
19 juin 2025IIDefective container; blister packaging inadequately sealed.The Harvard Drug Group LLC
27 mai 2025IICGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc.
27 mai 2025IICGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc.
22 avr. 2025IICGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.RemedyRePack Inc.
18 avr. 2025IIcGMP DeviationsPreferred Pharmaceuticals, Inc.
24 mars 2025IICGMP DeviationsRemedyRepack Inc.
17 mars 2025IIFailed dissolution specifications: lower than specificationsBIOCON PHARMA INC
13 mars 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mars 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mars 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mars 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mars 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mars 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mars 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
4 mars 2025IIICross ContaminationSUN PHARMACEUTICAL INDUSTRIES INC
4 mars 2025IIICross ContaminationSUN PHARMACEUTICAL INDUSTRIES INC
17 févr. 2025IIDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC
27 déc. 2024IIPresence of Particulate Matter: A market complaint was received of a glass piece in the vial.Eugia US LLC
17 déc. 2024IIFailed Dissolution Specifications:Amerisource Health Services LLC
6 déc. 2024IICGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.Aurobindo Pharma USA Inc
1 nov. 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov. 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov. 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov. 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov. 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov. 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
31 oct. 2024IIDefective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).Noven Pharmaceuticals Inc
24 sept. 2024IIPresence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.Nivagen Pharmaceuticals Inc
31 juil. 2024IIPresence of Foreign Tablets; 3 fused tablets of Metformin ER 500 mg were found in bottle of Gabapentin TabletsGranules Pharmaceuticals Inc.
26 juil. 2024IIPresence of Particulate Matter: Complaint received of a glass particle in the vial.Eugia US LLC

Classe I = probabilité raisonnable de préjudice grave · Classe II = temporaire ou réversible · Classe III = peu susceptible de causer un préjudice.

Statut d'enregistrement

Certains produits de Bryant Ranch Prepack ne sont pas enregistrés auprès de la FDA pour un usage humain. Pour les substances non enregistrées (peptides, SARMs sans enregistrement humain), aucun fournisseur légitime à usage humain n'existe. L'absence de filière d'approvisionnement est l'information de sécurité.